{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:40:54Z","timestamp":1767840054252,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jaci.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T13:01:22Z","timestamp":1493211682000},"page":"137-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1\u2013derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis\u2013like and psoriasis-like dermatitis"],"prefix":"10.1016","volume":"141","author":[{"given":"Won-Ju","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja-Hyun","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Gyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minah","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Yeon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-487X","authenticated-orcid":false,"given":"Myung Hyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.04.007_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New insights into atopic dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.04.007_bib2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14712598.2013.758708","article-title":"New era of biologic therapeutics in atopic dermatitis","volume":"13","author":"Guttman-Yassky","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaci.2017.04.007_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","article-title":"The 500 Dalton rule for the skin penetration of chemical compounds and drugs","volume":"9","author":"Bos","year":"2000","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nbt928","article-title":"Discovery of transdermal penetration enhancers by high-throughput screening","volume":"22","author":"Karande","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.04.007_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd1304","article-title":"Current status and future potential of transdermal drug delivery","volume":"3","author":"Prausnitz","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2017.04.007_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.04.007_bib11","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/jid.2009.133","article-title":"Epidermal barrier dysfunction in atopic dermatitis","volume":"129","author":"Cork","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/JID.2015.362","article-title":"Differential features between chronic skin inflammatory diseases revealed in skin-humanized psoriasis and atopic dermatitis mouse models","volume":"136","author":"Carretero","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms regulating skin immunity and inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2017.04.007_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nbt0204-165","article-title":"Breaching the skin's barrier to drugs","volume":"22","author":"Barry","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.04.007_bib20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.drudis.2015.06.007","article-title":"Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook","volume":"20","author":"Walter","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jaci.2017.04.007_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nm.2182","article-title":"Dissolving polymer microneedle patches for influenza vaccination","volume":"16","author":"Sullivan","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.04.007_bib22","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.1073\/pnas.1505405112","article-title":"Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery","volume":"112","author":"Yu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2017.04.007_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.gt.3302171","article-title":"Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC\/Nga mice","volume":"11","author":"Sakamoto","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaci.2017.04.007_bib24","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1038\/srep07618","article-title":"A pliable electroporation patch (ep-Patch) for efficient delivery of nucleic acid molecules into animal tissues with irregular surface shapes","volume":"5","author":"Wei","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2017.04.007_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in\u00a0vitro and in\u00a0vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.04.007_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/gt.2014.29","article-title":"Exploitation of Langerhans cells for in\u00a0vivo DNA vaccine delivery into the lymph nodes","volume":"21","author":"Toke","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaci.2017.04.007_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.12.006","article-title":"Peptides as skin penetration enhancers: mechanisms of action","volume":"199","author":"Kumar","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jaci.2017.04.007_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.111.180042","article-title":"Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002","volume":"338","author":"Uchida","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2017.04.007_bib29","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1016\/j.biomaterials.2012.04.056","article-title":"Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery","volume":"33","author":"Candan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jaci.2017.04.007_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/81359","article-title":"Conjugation of arginine oligomers to cyclosporin A\u00a0facilitates topical delivery and inhibition of inflammation","volume":"6","author":"Rothbard","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.04.007_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/jid.2011.49","article-title":"Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC\/Nga mice","volume":"131","author":"Kim","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt1193","article-title":"Transdermal protein delivery by a coadministered peptide identified via phage display","volume":"24","author":"Chen","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2017.04.007_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2014.11.015","article-title":"Topical delivery of Cyclosporine A\u00a0into the skin using SPACE-peptide","volume":"199","author":"Chen","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jaci.2017.04.007_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2007.05.031","article-title":"Transdermal delivery enhanced by magainin pore-forming peptide","volume":"122","author":"Kim","year":"2007","journal-title":"J Control Release"},{"key":"10.1016\/j.jaci.2017.04.007_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2012.04.012","article-title":"Cell-penetrating peptides: breaking through to the other side","volume":"18","author":"Koren","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jaci.2017.04.007_bib36","doi-asserted-by":"crossref","first-page":"8244","DOI":"10.1038\/ncomms9244","article-title":"dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis","volume":"6","author":"Lim","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2017.04.007_bib37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nprot.2010.39","article-title":"Assaying proliferation and differentiation capacity of stem cells using disaggregated adult mouse epidermis","volume":"5","author":"Jensen","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jaci.2017.04.007_bib38","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jaci.2017.04.007_bib39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbamem.2007.03.026","article-title":"Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies","volume":"1768","author":"Zidovetzki","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2017.04.007_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1083\/jcb.200908086","article-title":"Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling","volume":"188","author":"Koivusalo","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jaci.2017.04.007_bib41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1083\/jcb.123.5.1107","article-title":"Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation","volume":"123","author":"Wang","year":"1993","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jaci.2017.04.007_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R","article-title":"Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins","volume":"20","author":"Hileman","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.jaci.2017.04.007_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0960-9822(02)00697-8","article-title":"The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3","volume":"12","author":"Simoncic","year":"2002","journal-title":"Curr Biol"},{"key":"10.1016\/j.jaci.2017.04.007_bib44","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mi.2014.122","article-title":"PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis","volume":"8","author":"Spalinger","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/mend.16.1.0761","article-title":"A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus","volume":"16","author":"Aoki","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jaci.2017.04.007_bib46","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/MCB.01234-06","article-title":"T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6","volume":"27","author":"Lu","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaci.2017.04.007_bib47","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1172\/JCI59492","article-title":"T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice","volume":"121","author":"Wiede","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.04.007_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nri2262","article-title":"Treatment strategies for allergy and asthma","volume":"8","author":"Holgate","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib49","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/00007890-200206150-00023","article-title":"FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506","volume":"73","author":"Xu","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2017.04.007_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2340\/00015555-0748","article-title":"Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids","volume":"90","author":"Kirsner","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.04.007_bib51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2340\/0001555571452454","article-title":"Lack of efficacy of topical cyclosporin A\u00a0in atopic dermatitis and allergic contact dermatitis","volume":"71","author":"De Rie","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.04.007_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.02.040","article-title":"Skin penetration enhancers","volume":"447","author":"Lane","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jaci.2017.04.007_bib54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0149-2918(04)90183-X","article-title":"Evaluation of a low-dose lidocaine iontophoresis system for topical anesthesia in adults and children: a randomized, controlled trial","volume":"26","author":"Zempsky","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2017.04.007_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00299-5","article-title":"Phonophoresis: efficiency, mechanisms and skin tolerance","volume":"243","author":"Machet","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jaci.2017.04.007_bib56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2017.04.007_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4110\/in.2016.16.1.33","article-title":"Use of cell-penetrating peptides in dendritic cell-based vaccination","volume":"16","author":"Lim","year":"2016","journal-title":"Immune Netw"},{"key":"10.1016\/j.jaci.2017.04.007_bib58","doi-asserted-by":"crossref","first-page":"e0155689","DOI":"10.1371\/journal.pone.0155689","article-title":"Cell type preference of a novel human derived cell-permeable peptide dNP2 and TAT in murine splenic immune cells","volume":"11","author":"Lim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.04.007_bib59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbrc.2012.01.041","article-title":"Functionalization with C-terminal cysteine enhances transfection efficiency of cell-penetrating peptides through dimer formation","volume":"418","author":"Amand","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2017.04.007_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/bc100045s","article-title":"CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes","volume":"22","author":"Jha","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.jaci.2017.04.007_bib61","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10059-012-0284-y","article-title":"Identification of a novel cell-penetrating peptide from human phosphatidate phosphatase LPIN3","volume":"34","author":"Lim","year":"2012","journal-title":"Mol Cells"},{"key":"10.1016\/j.jaci.2017.04.007_bib62","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1007\/s11033-014-3711-7","article-title":"Cell membrane penetrating function of the nuclear localization sequence in human cytokine IL-1alpha","volume":"41","author":"Koo","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jaci.2017.04.007_bib63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.biophys.28.1.319","article-title":"Membrane protein folding and stability: physical principles","volume":"28","author":"White","year":"1999","journal-title":"Annu Rev Biophys Biomol Struct"},{"key":"10.1016\/j.jaci.2017.04.007_bib64","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1096\/fj.12-216176","article-title":"Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis","volume":"27","author":"Bechara","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2017.04.007_bib65","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1172\/JCI60001","article-title":"Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease","volume":"121","author":"Zikherman","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.04.007_bib66","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2016.10.004","article-title":"Advances in atopic dermatitis in 2015","volume":"138","author":"Nomura","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib67","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1081-1206(10)60153-6","article-title":"Intense tacrolimus ointment therapy in children with serious atopic eczema dermatitis syndrome","volume":"103","author":"Leonardi","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.04.007_bib69","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy","volume":"44","author":"Hanifin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.04.007_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5021\/ad.2010.22.1.9","article-title":"The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis","volume":"22","author":"Haw","year":"2010","journal-title":"Ann Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917306747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917306747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:09:30Z","timestamp":1758791370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917306747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0091674917306747"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.04.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1\u2013derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis\u2013like and psoriasis-like dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}